Nothing Special   »   [go: up one dir, main page]

SG11201507265XA - Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas - Google Patents

Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Info

Publication number
SG11201507265XA
SG11201507265XA SG11201507265XA SG11201507265XA SG11201507265XA SG 11201507265X A SG11201507265X A SG 11201507265XA SG 11201507265X A SG11201507265X A SG 11201507265XA SG 11201507265X A SG11201507265X A SG 11201507265XA SG 11201507265X A SG11201507265X A SG 11201507265XA
Authority
SG
Singapore
Prior art keywords
dihydroimidazo
quinazolines
substituted
treating lymphomas
lymphomas
Prior art date
Application number
SG11201507265XA
Inventor
Ningshu Liu
Katja Haike
Juliane Paul
Antje Margret Wengner
Original Assignee
Bayer Pharma Aktiengesllschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesllschaft filed Critical Bayer Pharma Aktiengesllschaft
Publication of SG11201507265XA publication Critical patent/SG11201507265XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201507265XA 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas SG11201507265XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13162710 2013-04-08
EP13184240 2013-09-13
PCT/EP2014/056768 WO2014166820A1 (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Publications (1)

Publication Number Publication Date
SG11201507265XA true SG11201507265XA (en) 2015-10-29

Family

ID=50439383

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201710539QA SG10201710539QA (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
SG11201507265XA SG11201507265XA (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201710539QA SG10201710539QA (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Country Status (28)

Country Link
US (2) US9999623B2 (en)
EP (1) EP2983669B1 (en)
JP (1) JP6368353B2 (en)
KR (1) KR102304108B1 (en)
CN (1) CN105263497B (en)
AP (1) AP2015008750A0 (en)
AU (1) AU2014253348B2 (en)
BR (1) BR112015025304B1 (en)
CA (1) CA2908776C (en)
CL (1) CL2015002978A1 (en)
CR (1) CR20150523A (en)
CU (1) CU24400B1 (en)
DO (1) DOP2015000256A (en)
EA (2) EA037577B1 (en)
ES (1) ES2708350T3 (en)
HK (1) HK1220121A1 (en)
IL (1) IL241543B (en)
JO (1) JOP20140141B1 (en)
MX (1) MX2015014171A (en)
MY (1) MY192626A (en)
NI (1) NI201500148A (en)
PE (1) PE20151780A1 (en)
PH (1) PH12015502317A1 (en)
SG (2) SG10201710539QA (en)
TN (1) TN2015000452A1 (en)
TW (2) TWI675663B (en)
UA (2) UA122822C2 (en)
WO (1) WO2014166820A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
US10124007B2 (en) 2013-12-03 2018-11-13 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
CN105017256A (en) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 Polyfluorinated compound Bruton tyrosine kinase inhibitor
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN107864625B (en) 2015-03-09 2021-05-28 拜耳制药股份公司 Combination products containing substituted 2, 3-dihydroimidazo [1,2-c ] quinazolines
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
PT3954690T (en) 2015-07-02 2023-06-06 Acerta Pharma Bv Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
EP3411497A1 (en) * 2016-02-01 2018-12-12 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
SG10202007322PA (en) * 2016-02-01 2020-09-29 Bayer Pharma AG Copanlisib biomarkers
CN108884098B (en) 2016-03-08 2021-09-14 拜耳制药股份公司 2-amino-N- [ 7-methoxy-2, 3-dihydroimidazo [1,2-c ] quinazolin-5-yl ] pyrimidine-5-carboxamides
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10689378B2 (en) * 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
US10676479B2 (en) * 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
WO2018054782A1 (en) * 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN109937041B (en) * 2017-05-18 2022-04-12 江苏恒瑞医药股份有限公司 Application of EZH2 inhibitor and BTK inhibitor in preparation of medicine for treating tumors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
RU2745397C1 (en) 2017-09-13 2021-03-24 Гуандун Оппо Мобайл Телекоммьюникейшнз Корп., Лтд. Method, terminal device and network data processing device
TW201922256A (en) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 Methods for treating lymphoid malignancies
CA3157789A1 (en) * 2019-10-15 2021-04-22 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
JP7440360B2 (en) 2020-06-30 2024-02-28 東日本旅客鉄道株式会社 Polishing equipment for angle steel materials
CN115120596A (en) * 2021-03-26 2022-09-30 上海璎黎药业有限公司 Quinazoline compound and application of pharmaceutical composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1364099A (en) 1919-09-10 1921-01-04 Flannery Bolt Co Staybolt structure for boilers
US1400975A (en) 1920-10-11 1921-12-20 Page Henry Benjiman Dirigible headlight for motor-vehicles
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2003277383A (en) * 2002-03-14 2003-10-02 Bayer Ag Optically active pyridine derivative and medicine containing the same
ES2367141T3 (en) 2002-09-30 2011-10-28 Bayer Pharma Aktiengesellschaft CONDENSED AZOL-PYRIMIDINE DERIVATIVES.
AR064106A1 (en) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS
WO2009091550A2 (en) 2008-01-14 2009-07-23 Bayer Healthcare Llc Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
CN102958540B (en) 2010-04-16 2015-09-02 拜耳知识产权有限责任公司 Containing the combination of 2,3-glyoxalidine also [1, the 2-C] quinazoline replaced
CA2797398C (en) 2010-05-14 2017-01-24 Lg Electronics Inc. Method for allocating resources in a wireless communication system and a device for the same
UA113280C2 (en) * 2010-11-11 2017-01-10 AMINOSPIRT-SUBSTITUTED Derivatives of 2,3-Dihydroimimidase $ 1,2-c] QINAZOLINE, SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, DISEASES AND DISEASES
JP5790016B2 (en) 2011-02-18 2015-10-07 コベルコ建機株式会社 Hybrid construction machinery
CA2820709C (en) * 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
WO2012121953A1 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (en) 2011-04-05 2021-01-31 Bayer Ip Gmbh Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines
CA2840687C (en) * 2011-07-01 2020-04-28 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
US20150141470A1 (en) * 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US8993891B2 (en) 2012-06-28 2015-03-31 Thomas & Betts International, Inc. Lift and pivot grommet
JP6499657B2 (en) 2013-12-03 2019-04-10 バイエル ファーマ アクチエンゲゼルシャフト Combination of PI3K inhibitors
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107864625B (en) 2015-03-09 2021-05-28 拜耳制药股份公司 Combination products containing substituted 2, 3-dihydroimidazo [1,2-c ] quinazolines
BR112017019190A2 (en) 2015-03-09 2018-04-24 Bayer Healthcare Pharmaceuticals Inc use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines

Also Published As

Publication number Publication date
TN2015000452A1 (en) 2017-04-06
BR112015025304B1 (en) 2022-09-27
PH12015502317A1 (en) 2016-02-10
ES2708350T3 (en) 2019-04-09
CR20150523A (en) 2016-01-29
EP2983669B1 (en) 2018-10-24
EA201591932A1 (en) 2016-04-29
TW201517909A (en) 2015-05-16
TWI675663B (en) 2019-11-01
WO2014166820A1 (en) 2014-10-16
AU2014253348B2 (en) 2019-05-23
US20180193349A1 (en) 2018-07-12
US10226469B2 (en) 2019-03-12
JP2016515601A (en) 2016-05-30
AP2015008750A0 (en) 2015-09-30
AU2014253348A1 (en) 2015-10-08
BR112015025304A2 (en) 2017-07-18
EP2983669A1 (en) 2016-02-17
KR20150138858A (en) 2015-12-10
MY192626A (en) 2022-08-29
US9999623B2 (en) 2018-06-19
KR102304108B1 (en) 2021-09-23
TWI689307B (en) 2020-04-01
EA201792650A1 (en) 2018-04-30
CU20150140A7 (en) 2016-10-28
EA037577B1 (en) 2021-04-16
DOP2015000256A (en) 2015-12-31
EA031493B1 (en) 2019-01-31
JP6368353B2 (en) 2018-08-01
SG10201710539QA (en) 2018-01-30
TW201924690A (en) 2019-07-01
JOP20140141B1 (en) 2021-08-17
PE20151780A1 (en) 2015-12-20
US20160058770A1 (en) 2016-03-03
CU24400B1 (en) 2019-04-04
NZ712033A (en) 2021-03-26
CA2908776A1 (en) 2014-10-16
UA119537C2 (en) 2019-07-10
CN105263497B (en) 2019-04-30
UA122822C2 (en) 2021-01-06
IL241543B (en) 2019-08-29
HK1220121A1 (en) 2017-04-28
CA2908776C (en) 2021-08-10
NI201500148A (en) 2015-11-30
EA031493B9 (en) 2019-12-18
CN105263497A (en) 2016-01-20
MX2015014171A (en) 2015-12-16
CL2015002978A1 (en) 2016-04-15

Similar Documents

Publication Publication Date Title
IL241543B (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
IL283943B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
HK1219280A1 (en) Methods of treating sporadic inclusion body myositis
HK1250645A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2968311A4 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
HK1223921A1 (en) New octahydro-cyclobuta [1,2-c;3,4-c]dipyrrol-2-yl -[12-c34-c]-2
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
HK1220324A1 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
IL244909B (en) Rapamycin for the treatment of lymphangioleiomyomatosis
HRP20190013T1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
SG10201801205YA (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
HK1217659A1 (en) Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use [12-b]
EP3733184C0 (en) Pyrimidine compounds for use in the treatment of cancer
HK1183708A1 (en) Determination method of cortex moutan
EP3013344A4 (en) Treating an arrhythmia with an opioid antagonist